RESUMEN
BACKGROUND: Previous studies have suggested that light rays may interact with contact lenses, potentially affecting their transmittance. AIM: This study aimed to investigate the effects of visible and ultraviolet (UV)-A light sources on the transmittance of some commercially available daily, weekly, and monthly contact lenses. METHODS: Nine commercially available soft contact lenses were irradiated with a solar simulator, light-emitting diode (LED) source, laser source, and UV-A source. The average transmittance of the tested lenses before and after irradiation in the UV, visible, and infrared light wavelength ranges was determined using an Agilent UV-visible spectrophotometer, model 8453. RESULTS: The results showed a partial or complete block of UV transmission at the UV-B region (300 nm) and the UV-A region (355 nm) by the Bio true daily contact lens, as well as the Acuvue Oasys, Avaira, and Biomedics 55 weekly lenses. At the visible region (555 nm), irradiation of the contact lenses by different light sources resulted in reduced light transmittance. At the infrared region (900 nm), the weekly and monthly contact lenses partially blocked infrared transmission, while the daily lenses showed either increased or decreased infrared transmission. CONCLUSIONS: Solar and artificial lighting, as well as high-powered lasers, constitute a major concern on the contact lenses' light transmission and optical properties. It is essential to develop soft contact lenses that have photoprotective properties while maintaining visible light transmittance.
RESUMEN
Low-oxygen conditions (hypoxia) have been associated primarily with cell-cycle arrest in dividing cells. Macrophages are typically quiescent in G0 but can proliferate in response to tissue signals. Here we show that hypoxia (1% oxygen tension) results in reversible entry into the cell cycle in macrophages. Cell cycle progression is largely limited to G0-G1/S phase transition with little progression to G2/M. This cell cycle transitioning is triggered by an HIF2α-directed transcriptional program. The response is accompanied by increased expression of cell-cycle-associated proteins, including CDK1, which is known to phosphorylate SAMHD1 at T592 and thereby regulate antiviral activity. Prolyl hydroxylase (PHD) inhibitors are able to recapitulate HIF2α-dependent cell cycle entry in macrophages. Finally, tumor-associated macrophages (TAMs) in lung cancers exhibit transcriptomic profiles representing responses to low oxygen and cell cycle progression at the single-cell level. These findings have implications for inflammation and tumor progression/metastasis where low-oxygen environments are common.
Asunto(s)
Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico , Ciclo Celular , Hipoxia de la Célula , Macrófagos , Macrófagos/metabolismo , Animales , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Humanos , Ratones , Ratones Endogámicos C57BL , Macrófagos Asociados a Tumores/metabolismoRESUMEN
BACKGROUND: Tenofovir/lamivudine/dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen for people with HIV (PWH), including those who were previously virologically suppressed on non-nucleoside reverse transcriptase inhibitors (NNRTIs). We sought to estimate the real-world effectiveness of the TLD transition in Ugandan public-sector clinics. METHODS: We conducted a prospective cohort study of PWH ≥18 years who were transitioned from NNRTI-based ART to TLD. Study visits were conducted on the day of TLD transition and 24- and 48- weeks later. The primary endpoint was viral suppression (<200â copies/mL) at 48-weeks. We collected blood for retrospective viral load (VL) assessment and conducted genotypic resistance tests for specimens with VL >500â copies/mL. RESULTS: We enrolled 500 participants (median age of 47 years; 41% women). At 48-weeks after TLD transition, 94% of participants were in care with a VL <200â copies/mL (n = 469/500); 2% (n = 11/500) were lost from care or died; and only 2% (n = 9/500) had a VL >500â copies/mL. No incident resistance to DTG was identified. Few participants (2%, n = 9/500) discontinued TLD due to adverse events. CONCLUSIONS: High rates of viral suppression, high tolerability, and lack of emergent drug resistance support use of TLD as the preferred first-line regimen in the region.
RESUMEN
Despite expanded antiretroviral therapy (ART) in South Africa, HIV-1 transmission persists. Integrase strand transfer inhibitors (INSTI) and long-acting injectables offer potential for superior viral suppression, but pre-existing drug resistance could threaten their effectiveness. In a community-based study in rural KwaZulu-Natal, prior to widespread INSTI usage, we enroled 18,025 individuals to characterise HIV-1 drug resistance and transmission networks to inform public health strategies. HIV testing and reflex viral load quantification were performed, with deep sequencing (20% variant threshold) used to detect resistance mutations. Phylogenetic and geospatial analyses characterised transmission clusters. One-third of participants were HIV-positive, with 21.7% having detectable viral loads; 62.1% of those with detectable viral loads were ART-naïve. Resistance to older reverse transcriptase (RT)-targeting drugs was found, but INSTI resistance remained low (<1%). Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, particularly to rilpivirine (RPV) even in ART-naïve individuals, was concerning. Twenty percent of sequenced individuals belonged to transmission clusters, with geographic analysis highlighting higher clustering in peripheral and rural areas. Our findings suggest promise for INSTI-based strategies in this setting but underscore the need for RPV resistance screening before implementing long-acting cabotegravir (CAB) + RPV. The significant clustering emphasises the importance of geographically targeted interventions to effectively curb HIV-1 transmission.
Asunto(s)
Farmacorresistencia Viral , Infecciones por VIH , VIH-1 , Filogenia , Población Rural , Carga Viral , Humanos , Infecciones por VIH/transmisión , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , Infecciones por VIH/epidemiología , Farmacorresistencia Viral/genética , Sudáfrica/epidemiología , VIH-1/genética , VIH-1/efectos de los fármacos , Femenino , Masculino , Adulto , Persona de Mediana Edad , Carga Viral/efectos de los fármacos , Adulto Joven , Fármacos Anti-VIH/farmacología , Fármacos Anti-VIH/uso terapéutico , Adolescente , Mutación , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Inhibidores de la Transcriptasa Inversa/farmacología , Inhibidores de Integrasa VIH/farmacología , Inhibidores de Integrasa VIH/uso terapéuticoRESUMEN
SARS-CoV-2 infection can cause severe pneumonia, wherein exacerbated inflammation plays a major role. This is reminiscent of the process commonly termed cytokine storm, a condition dependent on a disproportionated production of cytokines. This state involves the activation of the innate immune response by viral patterns and coincides with the biosynthesis of the biomass required for viral replication, which may overwhelm the capacity of the endoplasmic reticulum and drive the unfolded protein response (UPR). The UPR is a signal transduction pathway composed of three branches that is initiated by a set of sensors: inositol-requiring protein 1 (IRE1), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6). These sensors control adaptive processes, including the transcriptional regulation of proinflammatory cytokines. Based on this background, the role of the UPR in SARS-CoV-2 replication and the ensuing inflammatory response was investigated using in vivo and in vitro models of infection. Mice and Syrian hamsters infected with SARS-CoV-2 showed a sole activation of the Ire1α-Xbp1 arm of the UPR associated with a robust production of proinflammatory cytokines. Human lung epithelial cells showed the dependence of viral replication on the expression of UPR-target proteins branching on the IRE1α-XBP1 arm and to a lower extent on the PERK route. Likewise, activation of the IRE1α-XBP1 branch by Spike (S) proteins from different variants of concern was a uniform finding. These results show that the IRE1α-XBP1 system enhances viral replication and cytokine expression and may represent a potential therapeutic target in SARS-CoV-2 severe pneumonia.
Asunto(s)
COVID-19 , Endorribonucleasas , Proteínas Serina-Treonina Quinasas , SARS-CoV-2 , Respuesta de Proteína Desplegada , Replicación Viral , Proteína 1 de Unión a la X-Box , Animales , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Serina-Treonina Quinasas/genética , Endorribonucleasas/metabolismo , Endorribonucleasas/genética , Proteína 1 de Unión a la X-Box/metabolismo , Proteína 1 de Unión a la X-Box/genética , SARS-CoV-2/metabolismo , Humanos , COVID-19/metabolismo , COVID-19/virología , COVID-19/patología , COVID-19/inmunología , Ratones , Mesocricetus , Transducción de Señal , Ratones Endogámicos C57BL , Citocinas/metabolismo , FemeninoRESUMEN
BACKGROUND: People with HIV (PWH) on integrase inhibitor-based regimens may be at risk of excess weight gain, but it is unclear if this risk is consistent across settings. We assessed weight change over 48âweeks among PWH who were transitioned to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD). DESIGN: We conducted a prospective cohort study at public-sector HIV clinics in Uganda and South Africa. METHODS: Eligible participants were adults who were transitioned to TLD. Weight was measured at enrollment, 24-, and 48-weeks post TLD transition. Our outcomes were weight change, change in waist circumference, and clinically significant weight gain, defined as ≥10% increase in weight from baseline, over 48âweeks. We used linear mixed-effects regression models, adjusted for demographic factors, to estimate weight gain and identify risk factors. RESULTS: Weight data were available for 428 participants in Uganda and 367 in South Africa. The mean weight change was 0.6âkg [95% CI: 0.1-1.0] in Uganda and 2.9âkg [2.3-3.4] in South Africa ( P â<â0.001). The mean change in waist circumference was 0.8âcm [95% CI: 0.0-1.5]) in Uganda and 2.3âcm [95% CI: 1.4-3.2] in South Africa ( P â=â0.012). Clinically significant weight gain occurred in 9.8% [7.0-12.6] of participants in Uganda and 18.0% [14.1-21.9] in South Africa ( P â<â0.001). After adjustment, PWH gained significantly less weight in Uganda than in South Africa. CONCLUSIONS: PWH in South Africa experienced significantly greater weight gain and increases in waist circumference compared to Uganda. Strategies to address weight gain in PWH should be carefully considered and may vary by region.
Asunto(s)
Infecciones por VIH , Compuestos Heterocíclicos con 3 Anillos , Oxazinas , Piperazinas , Piridonas , Aumento de Peso , Humanos , Sudáfrica/epidemiología , Piridonas/uso terapéutico , Uganda/epidemiología , Masculino , Femenino , Infecciones por VIH/tratamiento farmacológico , Estudios Prospectivos , Adulto , Compuestos Heterocíclicos con 3 Anillos/uso terapéutico , Aumento de Peso/efectos de los fármacos , Oxazinas/uso terapéutico , Piperazinas/uso terapéutico , Persona de Mediana Edad , Inhibidores de Integrasa VIH/uso terapéutico , Fármacos Anti-VIH/uso terapéutico , Lamivudine/uso terapéutico , Tenofovir/uso terapéutico , Sustitución de Medicamentos , Adulto JovenRESUMEN
Immunological determinants favouring emergence of broadly neutralising antibodies are crucial to the development of HIV-1 vaccination strategies. Here, we combined RNAseq and B cell cloning approaches to isolate a broadly neutralising antibody (bnAb) ELC07 from an individual living with untreated HIV-1. Using single particle cryogenic electron microscopy (cryo-EM), we show that the antibody recognises a conformational epitope at the gp120-gp41 interface. ELC07 binds the closed state of the viral glycoprotein causing considerable perturbations to the gp41 trimer core structure. Phenotypic analysis of memory B cell subsets from the ELC07 bnAb donor revealed a lack of expected HIV-1-associated dysfunction, specifically no increase in CD21-/CD27- cells was observed whilst the resting memory (CD21+/CD27+) population appeared preserved despite uncontrolled HIV-1 viraemia. Moreover, single cell transcriptomes of memory B cells from this bnAb donor showed a resting memory phenotype irrespective of the epitope they targeted or their ability to neutralise diverse strains of HIV-1. Strikingly, single memory B cells from the ELC07 bnAb donor were transcriptionally similar to memory B cells from HIV-negative individuals. Our results demonstrate that potent bnAbs can arise without the HIV-1-induced dysregulation of the memory B cell compartment and suggest that sufficient levels of antigenic stimulation with a strategically designed immunogen could be effective in HIV-negative vaccine recipients.